The coronary sinus reducer (CSR) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion. We aimed to measure its efficacy, compared with placebo, on myocardial ischaemia reduction and symptom improvement.
Each week, we present a journal club in which we choose a study that we believe will be of interest to the interventional cardiology community and discuss it at a virtual journal club with several of our faculty members.
Panelists
Presenter
